Logo image of IBIO

IBIO INC (IBIO) Stock Fundamental Analysis

NASDAQ:IBIO - Nasdaq - US4510337086 - Common Stock - Currency: USD

0.8146  -0.01 (-1.26%)

After market: 0.8 -0.01 (-1.79%)

Fundamental Rating

2

Overall IBIO gets a fundamental rating of 2 out of 10. We evaluated IBIO against 558 industry peers in the Biotechnology industry. While IBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. IBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IBIO has reported negative net income.
In the past year IBIO has reported a negative cash flow from operations.
IBIO had negative earnings in each of the past 5 years.
In the past 5 years IBIO always reported negative operating cash flow.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of IBIO (-109.89%) is worse than 78.29% of its industry peers.
IBIO has a worse Return On Equity (-184.45%) than 65.30% of its industry peers.
Industry RankSector Rank
ROA -109.89%
ROE -184.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

IBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -25.77, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
IBIO's Altman-Z score of -25.77 is on the low side compared to the rest of the industry. IBIO is outperformed by 87.37% of its industry peers.
There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.77
ROIC/WACCN/A
WACC10.78%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.12 indicates that IBIO should not have too much problems paying its short term obligations.
With a Current ratio value of 1.12, IBIO is not doing good in the industry: 85.59% of the companies in the same industry are doing better.
IBIO has a Quick Ratio of 1.12. This is a normal value and indicates that IBIO is financially healthy and should not expect problems in meeting its short term obligations.
IBIO has a worse Quick ratio (1.12) than 84.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.33%, which is quite impressive.
Looking at the last year, IBIO shows a very strong growth in Revenue. The Revenue has grown by 650.00%.
The Revenue for IBIO have been decreasing by -35.53% on average. This is quite bad
EPS 1Y (TTM)86.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.99%
Revenue 1Y (TTM)650%
Revenue growth 3Y-54.38%
Revenue growth 5Y-35.53%
Sales Q2Q%N/A

3.2 Future

IBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
IBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y78.54%
EPS Next 2Y34.7%
EPS Next 3Y24.06%
EPS Next 5Y13.67%
Revenue Next Year1100%
Revenue Next 2Y226.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2031 2032 10M 20M 30M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

IBIO's earnings are expected to grow with 24.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.7%
EPS Next 3Y24.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IBIO INC

NASDAQ:IBIO (7/11/2025, 8:22:21 PM)

After market: 0.8 -0.01 (-1.79%)

0.8146

-0.01 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2025-05-02/bmo
Earnings (Next)09-18 2025-09-18/amc
Inst Owners15.78%
Inst Owner Change0%
Ins Owners4.64%
Ins Owner Change0%
Market Cap13.46M
Analysts82.22
Price Target4.9 (501.52%)
Short Float %5.26%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.21%
Min EPS beat(2)-50.12%
Max EPS beat(2)-2.3%
EPS beat(4)1
Avg EPS beat(4)-33.84%
Min EPS beat(4)-88.99%
Max EPS beat(4)6.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-33.33%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.89
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-2.34
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.02
BVpS0.69
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.89%
ROE -184.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -25.77
F-Score4
WACC10.78%
ROIC/WACCN/A
Cap/Depr(3y)332.24%
Cap/Depr(5y)252.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.99%
EPS Next Y78.54%
EPS Next 2Y34.7%
EPS Next 3Y24.06%
EPS Next 5Y13.67%
Revenue 1Y (TTM)650%
Revenue growth 3Y-54.38%
Revenue growth 5Y-35.53%
Sales Q2Q%N/A
Revenue Next Year1100%
Revenue Next 2Y226.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-41.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.96%
OCF growth 3YN/A
OCF growth 5YN/A